

CITATION REPORT

List of articles citing

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus

DOI: 10.1177/0961203306071872

Lupus, 2006, 15, 577-83.

Source: <https://exaly.com/paper-pdf/41282762/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
319	Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). 2007 , 66, 1168-72		320
318	Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. <i>Lupus</i> , 2007 , 16, 401-9	2.6	126
317	Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. 2007 , 66, 815-7		65
316	Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. <i>Lupus</i> , 2007 , 16, 810-6	2.6	58
315	Atherosclerosis and central nervous system involvement in systemic lupus erythematosus. 2007 , 13, 179-80		
314	Bibliography. Current world literature. Systemic lupus erythematosus and Sjögren's syndrome. 2007 , 19, 499-508		
313	New concepts in antimalarial use and mode of action in dermatology. 2007 , 20, 160-74		185
312	The treatment of antiphospholipid syndrome: a harmonic contrast. 2007 , 21, 1079-92		13
311	[Modern therapy for systemic lupus erythematosus]. 2007 , 66, 662-6, 668-71		4
310	INFLAMMOPHARMACOLOGY. 2008 , 16, 286		1
309	Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. 2009 , 61, 29-36		227
308	Drugs to Treat Systemic Lupus Erythematosus: Relationship between Current Use and Cardiovascular Risk Factors. 2008 , 1, 23-28		8
307	Factores asociados a la mortalidad del lupus eritematoso sistémico. 2008 , 9, 219-234		7
306	Lessons from LUMINA: a multiethnic US cohort. <i>Lupus</i> , 2008 , 17, 971-6	2.6	17
305	[Systemic lupus erythematosus: news and therapeutic perspectives]. 2008 , 37, 444-59		4
304	[Mortality and prognostic factors in 146 patients with systemic lupus erythematosus in southern Tunisia]. 2008 , 37, 1711-6		0
303	[Hydroxychloroquine and systemic lupus: a reappraisal]. 2008 , 29, 735-7		9

302	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , 2008 , 17, 281-8	2.6	120
301	Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. 2008 , 47, 920-3		350
300	Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). 2008 , 67, 829-34		75
299	Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. <i>Lupus</i> , 2008 , 17, 849-59	2.6	62
298	Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. 2008 , 35, 2152-8		229
297	Hydroxychloroquine: the cornerstone of lupus therapy. <i>Lupus</i> , 2008 , 17, 271-3	2.6	51
296	New approaches for managing antiphospholipid syndrome. 2009 , 5, 160-70		45
295	Venous thrombosis in the antiphospholipid syndrome. 2009 , 29, 321-5		40
294	Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. <i>Lupus</i> , 2009 , 18, 508-15	2.6	37
293	Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. <i>Lupus</i> , 2009 , 18, 1019-256		50
292	Managing lupus patients during pregnancy. 2009 , 23, 575-82		30
291	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. 2009 , 61, 830-9		175
290	Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel et al. 2009 , 61, 1614-5; author reply 1615-6		5
289	[Antimalarials. A treatment option for every lupus patient!?!]. 2009 , 68, 584, 586-90		4
288	[The antiphospholipid syndrome in the 21st century]. 2009 , 133, 390-6		2
287	Management of antiphospholipid syndrome. 2009 , 33, 92-8		54
286	Thrombosis in systemic lupus erythematosus: risk and protection. 2009 , 7, 1541-9		23
285	Predictors of major infections in systemic lupus erythematosus. 2009 , 11, R109		222

284	Chapter 15 Treatment of Thrombosis in the Antiphospholipid Syndrome. 2009 , 185-191	
283	Current management of antiphospholipid syndrome-related thrombosis. 2009 , 7, 1551-8	7
282	Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. 2009 , 10, 601-14	10
281	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. 2009 , 68, 1428-32	220
280	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. 2009 , 42, 257-9	26
279	Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. 2009 , 15, 111-6	32
278	Risk factors for thrombotic events in patients with systemic lupus erythematosus from different ethnic groups. 2009 , 4, 267-269	1
277	Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. 2010 , 115, 2292-9	179
276	A novel antiphospholipid antibody agent?. 2010 , 115, 2124-5	6
275	Management of the antiphospholipid syndrome. 2010 , 1, 15-22	4
274	Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. 2010 , 77, 4-5	26
273	Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. 2010 , 62, 386-92	29
272	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. 2010 , 62, 881-7	132
271	Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. 2010 , 62, 855-62	145
270	Reply. 2010 , 62, 2824-2825	
269	Pourquoi faut-il traiter tous les patients atteints de lupus systémique par hydroxychloroquine ?. 2010 , 77, 4-6	
268	Cardiovascular risk factors in primary Sjögren's syndrome: a case-control study in 624 patients. <i>Lupus</i> , 2010 , 19, 941-8	2.6 58
267	Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. 2010 , 6, 10-1	31

266	The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. <i>Lupus</i> , 2010 , 19, 460-9	2.6	103
265	Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?. <i>Lupus</i> , 2010 , 19, 475-856		49
264	TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. 2010 , 184, 5645-53		57
263	Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. 2010 , 89, 300-307		41
262	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
261	[Therapeutic strategies in antiphospholipid syndrome]. 2010 , 6, 37-42		4
260	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. 2010 , 69, 20-8		645
259	Therapeutic strategies in antiphospholipid syndrome. 2010 , 6, 37-42		
258	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29		166
257	Advances in the medical treatment of rheumatoid arthritis. 2011 , 27, 11-20		116
256	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. 2011 , 14, 1-5		5
255	Survival rate among Thai systemic lupus erythematosus patients in the era of aggressive treatment. 2011 , 14, 353-60		5
254	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. 2011 , 10, 705-14		61
253	Antimalarials and SLE. 2011 , 1061-1081		0
252	Treatment of Antiphospholipid Syndrome. 2011 , 1027-1042		
251	Therapeutic Perspectives in the Antiphospholipid Syndrome. 2011 , 7, 313-321		
250	[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine]. 2011 , 100, 2960-5		2
249	Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. 2011 , 13, 77-80		143

248	Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?. 2011 , 13, 59-69		55
247	Analytical interference of quinolone antibiotics and quinine derived drugs on urinary protein determined by reagent strips and the pyrogallol red-molybdate protein assay. 2011 , 44, 1000-4		9
246	Systemic lupus erythematosus in Hispanics. 2011 , 44, 555-61		12
245	Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. 2011 , 7, 227-41		72
244	ANTIPHOSPHOLIPID SYNDROME. 2011 , 344-360		2
243	Systemic lupus erythematosus risk factors for coronary artery calcifications. 2012 , 51, 110-9		62
242	Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. 2012 , 38, 339-47		28
241	Healthcare quality in systemic lupus erythematosus: using Donabedian® conceptual framework to understand what we know. 2012 , 7, 95-107		7
240	Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. <i>Lupus</i> , 2012 , 21, 830-5	2.6	113
239	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. 2012 , 71, 1502-9		115
238	Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). 2012 , 22, 249-255		10
237	Outcome of patients with membranous lupus nephritis in Cape Town South Africa. 2012 , 27, 3509-15		26
236	Immunotherapies in rheumatologic disorders. 2012 , 96, 475-96, ix-x		28
235	Venous thromboembolic disease in systemic autoimmune diseases: an association to keep in mind. 2012 , 12, 289-94		10
234	Lupus in Hispanics: a matter of serious concern. 2012 , 79, 824-34		10
233	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78		73
232	Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. 2012 , 14, R155		148
231	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. 2012 , 8, 522-33		145

230	Antiphospholipid syndrome in obstetrics. 2012 , 26, 65-76		45
229	Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. 2012 , 39, 531-5		19
228	Chloroquine: modes of action of an undervalued drug. 2013 , 153, 50-7		92
227	Top 10 clinical research developments in antiphospholipid syndrome. 2013 , 15, 367		3
226	Is there an effective treatment for late-onset systemic lupus erythematosus?. 2013 , 9, 437-450		
225	Antimalarial Medications. 2013 , 601-608		3
224	Management of women with systemic lupus erythematosus. 2013 , 75, 207-14		9
223	The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 77-95	5.3	212
222	Excess weight and associated risk factors in patients with systemic lupus erythematosus. 2013 , 33, 681-8		11
221	Innate immune processes in lupus erythematosus. 2013 , 147, 216-22		27
220	Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. 2013 , 17, 894-906		28
219	[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. 2013 , 141, 533-42		8
218	Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 2013 , 46, 363-8		23
217	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 264-72	5.3	88
216	Transient ischemic attack and stroke in systemic lupus erythematosus. <i>Lupus</i> , 2013 , 22, 1251-8	2.6	27
215	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. 2013 , 40, 831-41		79
214	Atherosclerosis in systemic lupus erythematosus. 2013 , 62, 255-62		45
213	Causes and predictors of mortality in hospitalized lupus patient in Sarawak General Hospital, Malaysia. <i>Lupus</i> , 2013 , 22, 106-11	2.6	42

212	Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. 2013 , 40, 30-3	70
211	Commentary on "The risky business of studying prognosis". 2013 , 40, 1771	1
210	Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. 2013 , 68, 766-71	97
209	Pathogenesis and Treatment of Atherosclerosis in Lupus. 2013 , 341-351	2
208	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62	27
207	Cardiovascular involvement in autoimmune diseases. 2014 , 2014, 367359	39
206	Treatment of membranous lupus nephritis. 2014 , 3, 106-113	1
205	Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety. 2014 , 2014, 348726	5
204	The risk of ischemic stroke in major rheumatic disorders. 2014 , 277, 1-5	15
203	Pharmacology of Chloroquine and Hydroxychloroquine. 2014 , 35-63	65
202	Prolonged remission in SLE revisited: an old wine in a new bottle. 2014 , 41, 1728-31	2
201	Antipalúdicos en dermatologí: mecanismo de acci3n, indicaciones y efectos secundarios. 2014 , 105, 243-252	27
200	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. 2014 , 73, 958-67	388
199	Ten common mistakes in the management of lupus nephritis. 2014 , 63, 667-76	28
198	Pragmatic approaches to therapy for systemic lupus erythematosus. 2014 , 10, 97-107	65
197	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. 2014 , 13, 685-96	248
196	Prednisone in lupus nephritis: how much is enough?. 2014 , 13, 206-14	48
195	Contraception and Pregnancy in Patients with Rheumatic Disease. 2014 ,	3

194	[Atherosclerosis in systemic lupus erythematosus]. 2014 , 43, 1034-47		9
193	Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. 2014 , 47, 67-76		43
192	Recent advances in the treatment of systemic lupus erythematosus. 2014 , 9, 89-100		
191	Antimalarials in dermatology: mechanism of action, indications, and side effects. 2014 , 105, 243-52		14
190	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80		101
189	Pathogenesis and treatment of atherosclerosis in lupus. 2014 , 40, 475-95, viii		17
188	Prevention and management of co-morbidities in SLE. 2014 , 43, e187-95		21
187	Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. 2015 , 1, FSO26		21
186	Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. 2015 , 67, 2176-84		87
185	Metabolic syndrome in patients with systemic lupus erythematosus: Causes and consequences. 2015 , 144, 309-311		
184	Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. 2015 , 10, e0139226		16
183	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches. 2015 , 2015, 951424		37
182	Chloroquine-containing compounds: a patent review (2010 - 2014). 2015 , 25, 1003-24		19
181	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 720-9	2.6	18
180	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. 2015 , 14, 358-62		84
179	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. 2015 , 49, 317-26		77
178	Recent advances in understanding the pathogenesis of atherosclerosis in CKD patients. 2015 , 25, 205-8		7
177	Lupus in Latin-American patients: lessons from the GLADEL cohort. <i>Lupus</i> , 2015 , 24, 536-45	2.6	39

176	CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. 2015 , 63, 59-67		29
175	[Metabolic syndrome in patients with systemic lupus erythematosus: causes and consequences]. 2015 , 144, 309-11		1
174	[Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients]. 2015 , 38, 377-87		1
173	Reviewing the recommendations for lupus in children. 2015 , 17, 17		9
172	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. 2015 , 42, 2092-7		98
171	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. 2015 , 14, 1373-85		15
170	Systemic lupus erythematosus: review of synthetic drugs. 2015 , 16, 2793-806		14
169	Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. <i>Lupus</i> , 2015 , 24, 299-306	2.6	12
168	The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. 2015 , 35, 153-7		9
167	Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. <i>Lupus</i> , 2015 , 24, 210-7	2.6	62
166	Antiphospholipid Antibody Syndrome. 2015 ,		1
165	Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. 2015 , 14, 23-9		46
164	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. 2016 , 115, 285-90		48
163	Current and emerging treatment options in the management of lupus. 2016 , 5, 9-20		28
162	[Hydroxychloroquine for autoimmune diseases]. 2016 , 144, 232-40		13
161	Immunomodulators in SLE: Clinical evidence and immunologic actions. 2016 , 74, 73-84		54
160	Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al. 2016 , 68, 1052-3		0
159	Reply. 2016 , 68, 1053-4		1

158	Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. 2016 , 68, 1295-302		58
157	What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?. 2016 , 2016, 714-716		18
156	Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. 2016 , 64, 908-10		12
155	Anti-malarials: Are There Benefits Beyond Mild Disease?. 2016 , 2, 1-12		5
154	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. 2016 , 18, 26		10
153	Connective Tissue Disease. 2016 ,		1
152	Conventional Treatment of Systemic Lupus Erythematosus. 2016 , 213-238		
151	Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. <i>Clinical Rheumatology</i> , 2016 , 35, 2219-27	3.9	11
150	Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. 2016 , 76, 459-83		91
149	Towards new avenues in the management of lupus glomerulonephritis. 2016 , 12, 221-34		57
148	The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. 2016 , 214, 273.e1-273.e8		92
147	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. 2017 , 69, 252-256		7
146	Treatment of Thrombosis in Antiphospholipid Syndrome. 2017 , 12, 231-241		
145	Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus. 2017 , 44, 1032-1038		58
144	Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. <i>Lupus</i> , 2017 , 26, 1407-1419	2.6	10
143	Epidemiology of systemic lupus erythematosus. 2017 , 13, 799-814		92
142	Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. 2017 , 158, 1538-1545		11
141	Predictors of incident proteinuria among patients with SLE. 2017 , 4, e000200		12

140	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. 2017 , 43, 562-571		60
139	Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. 2017 , 69, 791-799		54
138	Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. 2017 , 56, 2212-2221		13
137	Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. <i>Lupus</i> , 2017 , 26, 1463-1472	2.6	26
136	Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil. <i>Clinical Rheumatology</i> , 2017 , 36, 2005-2010	3.9	8
135	Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. 2017 , 4, e000209		12
134	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. 2017 , 65, 17-24		58
133	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. 2017 , 13, 35-41		21
132	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. 2017 , 617-643		0
131	Refugee Policy Implications of U.S. Immigration Medical Screenings: A New Era of Inadmissibility on Health-Related Grounds. 2017 , 14,		7
130	Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. 2018 , 72, e13095		12
129	Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood. 2018 , 32, e4258		9
128	Systemic lupus erythematosus and systemic sclerosis: All roads lead to platelets. 2018 , 17, 625-635		43
127	Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study. 2018 , 21, 1591-1599		10
126	Antiphospholipid syndrome. 2018 , 4, 17103		128
125	New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. 2018 , 17, 660-664		21
124	Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. 2018 , 35, 439-456		21
123	The non-haemostatic role of platelets in systemic lupus erythematosus. 2018 , 14, 195-213		49

122	Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. <i>Lupus</i> , 2018 , 27, 722-727	2.6	38
121	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. 2018 , 77, 98-103		117
120	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. 2018 , 45, 90-94		12
119	Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. <i>Lupus</i> , 2018 , 27, 399-406	2.6	39
118	Toxicidade retiniana pela hidroxicloroquina: frequência em um ambulatório de Oftalmologia. 2018 , 77,		
117	The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. 2018 , 9, 6615-6622		18
116	Organ damage in a cohort of Colombian patients with systemic lupus erythematosus: Characterization and associated factors. 2018 , 25, 85-91		
115	Thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2018 , 27, 21-27	2.6	2
114	Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. 2018 , 14, 693-703		99
113	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. 2018 , 17, 1153-1168		43
112	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. 2018 , 2018, 3424136		35
111	Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre. 2018 , 5, e000249		9
110	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. 2018 , 12, 1685-1695		53
109	Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. 2018 , 30, 482-489		30
108	Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus. 2018 , 13, e0188695		5
107	Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article. 2018 , 26, 1141-1149		45
106	Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. 2018 , 57, 1743-1751		23
105	Management of Psychosis in Neuropsychiatric Lupus. 2019 , 19, 9-17		1

104	Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. 2019 , 6, e000321		9
103	Predictors of predominant Lupus Low Disease Activity State (LLDAS-50). <i>Lupus</i> , 2019 , 28, 1648-1655	2.6	15
102	Take a look at the eyes in Systemic Lupus Erythematosus: A novel point of view. 2019 , 18, 247-254		17
101	Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome. 2019 , 21, 56		9
100	Case 17-2019: A 44-Year-Old Man with Joint Pain, Weight Loss, and Chest Pain. 2019 , 380, 2157-2167		1
99	Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. <i>Lupus</i> , 2019 , 28, 862-867	2.6	14
98	Real-world electronic health record identifies antimalarial underprescribing in patients with lupus nephritis. <i>Lupus</i> , 2019 , 28, 977-985	2.6	3
97	Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. 2019 , 9, e025649		12
96	Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. <i>Lupus</i> , 2019 , 28, 555-559 ²⁶		10
95	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. 2019 , 41, 476-482		10
94	Antimalarial Medications. 2019 , 650-660		
93	Systemic lupus erythematosus: Diagnosis and clinical management. 2019 , 96, 1-13		175
92	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. 2019 , 78, 372-379		32
91	Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells. 2019 , 23, 448-454		6
90	Under crossfire: thromboembolic risk in systemic lupus erythematosus. 2019 , 58, 940-952		13
89	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. 2019 , 71, 134-141		23
88	2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine. 2020 , 79, e114		3
87	Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine. 2020 , 79, e133		2

86 Systemic Lupus Erythematosus. **2020**, 555-573

85 Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. **2020**, 72, 448-453 50

84 Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. **2020**, 23, 1-9 17

83 Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. **2020**, 72, 225-232 8

82 Neuropsychiatric SLE: From Immune Mechanisms to Clinical Management. **2020**, 1

81 Treatment of antiphospholipid syndrome. **2020**, 221, 108597 4

80 Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. **2020**, 216, 107672 31

79 Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. **2020**, 262, 118541 4

78 Update on antimalarials and systemic lupus erythematosus. **2020**, 32, 572-582 6

77 Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. **2020**, 34, e14118 2

76 Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. **2020**, 59, v69-v81 16

75 Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. **2020**, 7, e613-e623 4

74 Effects of treatment with hydroxychloroquine on the modulation of Th17/Treg ratio and pregnancy outcomes in women with recurrent implantation failure: clinical trial. **2020**, 42, 632-642 7

73 Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. **2020**, 22, 191 8

72 Hydroxychloroquine is protective to the heart, not harmful: a systematic review. **2020**, 37, 100747 11

71 A Sensitive and Optimized HPLC-FLD Method for the Simultaneous Quantification of Hydroxychloroquine and Its Two Metabolites in Blood of Systemic Lupus Erythematosus Patients. **2020**, 58, 600-605 3

70 The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. **2020**, 158, 104904 72

69 Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population. **2021**, 73, 1219-1223 5

68	Management of cardiovascular disease in patients with systemic lupus erythematosus. 2020 , 21, 1617-1628	5
67	Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. 2020 , 9,	2
66	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32	24
65	The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. 2020 , 22, 159	1
64	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1150-1157	5:3 29
63	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. 2020 , 19, 102491	38
62	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. 2020 , 2, 335-343	85
61	Treatment of thrombotic antiphospholipid syndrome in adults and children. 2020 , 32, 215-227	2
60	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. 2021 , 60, 207-216	15
59	Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. 2021 , 84, 930-937	8
58	Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. 2021 , 60, 1774-1783	4
57	Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design. 2021 , 52, 36-44	1
56	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0
55	Impact of Antimalarial Adherence on Mortality among Patients with Newly Diagnosed Systemic Lupus Erythematosus: A Population-based Cohort Study. 2021 ,	4
54	Cardiovascular disease in lupus. 2021 , 503-519	
53	Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases. 2021 , 5, 259-264	
52	Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy. 2021 , 16, e0247052	2
51	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. 2021 , 54, 37-45	2

50	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. 2021 , 8,	2
49	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021 , 30, 1790-1798	2.6
48	Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome. 2021 , 90, 114-115	0
47	Antimalarial-induced retinal toxicity. 2021 , 28, 132-132	0
46	Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.. 2021 , 7, 560-575	1
45	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. 2021 , 100, S1-S276	91
44	Antimalarial drugs (and lupus). 2021 , 601-609	
43	Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers. 2021 , 9,	2
42	Kidney disease. 2021 , 471-502	
41	Antiphospholipid Syndrome. 2014 , 109-137	4
40	Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). 2012 , 22, 249-55	7
39	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. 2020 , 18, 549-565	19
38	Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. 2019 , 15, 2-6	3
37	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. 2019 , 30, 7-15	16
36	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. 2019 , 8,	25
35	Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Potential for Improved Primary Prevention With Statins. 2021 , 29, 323-327	0
34	Atherosclerosis in the Rheumatic Diseases: Compounding the Age Risk. 2011 , 17-25	
33	Treatment of non-renal lupus. 2011 , 1307-1316.e4	

32	What are the Potential Future Treatments in Antiphospholipid Syndrome?. 2012 , 261-287		
31	Antiphospholipid Antibody Carriers. 2015 , 207-218		
30	Daño de Hígano en una cohorte de pacientes colombianos con lupus eritematoso sistémico: caracterización y factores asociados. 2018 , 25, 85-91		1
29	Antipalúdicos de síntesis en dermatología. 2020 , 54, 1-11		
28	Cardiovascular disease in systemic lupus erythematosus. 2021 , 2, 157-172		0
27	Systemic Lupus Erythematosus and Cardiovascular Disease.. 2022 , 14, e22027		0
26	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. 2021 ,		4
25	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. 2022 , 14, 1759720X211073001		
24	Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.. <i>Lupus</i> , 2022 , 9612033221090127	2.6	0
23	Mechanism of Action and Efficacy of Immunosuppressors in Lupus Nephritis.. 2021 , 14, 441-458		2
22	Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine treated systemic lupus erythematosus patients.. 2022 ,		0
21	Case 12-2022: A 41-Year-Old Woman with Transient Ischemic Attack and Mitral Valve Masses.. 2022 , 386, 1560-1570		
20	Drug monitoring in systemic lupus erythematosus.. 2022 , 64, 102225		
19	2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists. <i>Reumatologia</i> , 2022 , 60, 125-132		1.7
18	Perioperative Management of Patients with Rheumatic Disease: Cardiovascular Risks, Prevention of Infectious and Thromboembolic Complications, Other Conditions. <i>Russian Archives of Internal Medicine</i> , 2022 , 12, 175-186		0.6
17	Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. <i>Frontiers in Immunology</i> , 13,	8.4	2
16	Outcomes following antimalarial withdrawal in patients with quiescent systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152046	5.3	
15	Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. <i>Lupus</i> , 096120332211156	2.6	0

14	Ultrasonic Synthesis and Preliminary Evaluation of Anticoronaviral Activity of 6,7-Dimethoxy-4-(4-(4-methoxyphenyl)piperazin-1-yl)-1-methylquinolin-1-ium Iodide. <i>MolBank</i> , 2022 , 2022, M1400	0.5
13	Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. <i>Clinical Rheumatology</i> ,	3.9
12	Recent Advances in SLE Treatment Including Biologic Therapies.	
11	Development of a child-friendly oral drug formulation using liposomal multilamellar vesicle technology. 2022 , 625, 122107	
10	Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. 096120332211297	○
9	The Association of Hydroxychloroquine Dosing with Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus.	○
8	Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. 2022 , 14, 2551	○
7	Hydroxychloroquine Dose and Risk for Incident Retinopathy.	○
6	A 27-Year-Old Woman With Dysarthria. 2023 , 38,	○
5	Autoimmune diseases. 2023 , 123-244	○
4	The role of platelets in immune-mediated inflammatory diseases.	○
3	Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial.	○
2	Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch. 096120332311651	○
1	The HAVEN studyHydroxychloroquine in ANCA vasculitis evaluation¶ multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. 2023 , 24,	○